1 |
Atchaneeyasakul L, Wongsiwaroj C, Uiprasertkul M, et al (2009). Prognostic factors and treatment outcomes of retinoblastoma in pediatric patients: a single-institution study. Jap J Ophthalmol, 53, 35-9.
DOI
|
2 |
Aerts I, Sastre-Garau X, Savignoni A, et al (2013). Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol, 31, 1458-63.
DOI
ScienceOn
|
3 |
Balwierz W, Pietrys D, Romanowska-Dixon B, et al (2010). Results of combined chemotherapy and local ophtalmic therapy for intraocular retinoblastoma. Przegl Lek, 67, 404-8.
|
4 |
Berry JL, Jubran R, Kim JW, et al (2013). Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer, 60, 688-93.
DOI
ScienceOn
|
5 |
Huang D, Zhang Y, Zhang W, et al (2013). Study on clinical therapeutic effect including symptoms, eye preservation rate, and follow-up of 684 children with retinoblastoma. Eur J Ophthalmol, 23, 532-8.
DOI
ScienceOn
|
6 |
Khan ZN, Sabir M, Kayani MA, et al (2013). Acetylation of retinoblastoma like protein2 (Rb2/p130) in tumor tissues. Asian Pac J Cancer Prev, 14, 2255-8.
과학기술학회마을
DOI
ScienceOn
|
7 |
Kim JM, Kim JH, Kim SJ, et al (2010). Visual prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy plus local treatments. Korean J Ophthalmol, 24, 347-52.
과학기술학회마을
DOI
ScienceOn
|
8 |
Li J, Xu ZW, Wang KH, et al (2013). Networks of MicroRNAs and genes in retinoblastomas. Asian Pac J Cancer Prev, 14, 6631-6.
과학기술학회마을
DOI
ScienceOn
|
9 |
Lambert MP, Shields C, Meadows AT (2008). A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer, 50, 223-6.
DOI
ScienceOn
|
10 |
Künkele A, Jurklies C, Wieland R, et al (2013). Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre. Br J Ophthalmol, 97, 1277-83.
DOI
ScienceOn
|
11 |
Peterson EC, Elhammady MS, Quintero-Wolfe S, et al (2011). Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors: Clinical article. J Neurosurg, 114, 1603-8.
DOI
ScienceOn
|
12 |
Shields CL, Honavar SG, Meadows AT, et al (2002). Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol, 133, 657-64.
DOI
ScienceOn
|
13 |
Shields CL, Shelil A, Cater J, et al (2003). Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol, 121, 1571-6.
DOI
ScienceOn
|
14 |
Shields CL, Shields JA (2010). Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol, 21, 203-12.
DOI
ScienceOn
|
15 |
Shin JY, Kim JH, Yu YS, et al (2010). Eye-preserving therapy in retinoblastoma: prolonged primary chemotherapy alone or combined with local therapy. Korean J Ophthalmol, 24, 219-24.
과학기술학회마을
DOI
ScienceOn
|
16 |
Turaka K, Shields CL, Meadows AT, et al (2012). Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer, 59, 121-5.
DOI
ScienceOn
|
17 |
Srivastava V, Patel B, Kumar M, et al (2013). Cyclin D1, retinoblastoma and p16 protein expression in carcinoma of the gallbladder. Asian Pac J Cancer Prev, 14, 2711-5.
과학기술학회마을
DOI
ScienceOn
|